NCT06419621
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer treatment 3 recruiting NCT03206203
Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer treatment 2 active_not_recruiting NCT03002103
A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer treatment 3 suspended NCT01351103
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands treatment 1 active_not_recruiting NCT02734290
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer treatment 1 / 2 active_not_recruiting NCT05252390
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors treatment 1 / 2 recruiting NCT04914390
A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer treatment 2 recruiting NCT06279364
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer treatment 3 recruiting NCT06291064
Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer treatment 2 not_yet_recruiting NCT06238921
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases treatment 1 / 2 not_yet_recruiting NCT05404321
Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatment No drug interventions Not Available Not Available recruiting NCT03945721
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients treatment 1 recruiting NCT06409221
VISION: Triple Negative Breast Cancer Sample and Clinical Data Acquisition Study No drug interventions Not Available Not Available enrolling_by_invitation NCT03125902
A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) treatment 3 completed NCT04916002
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer treatment 2 active_not_recruiting NCT01837602
cMet CAR RNA T Cells Targeting Breast Cancer No drug interventions treatment 1 completed NCT04260802
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers treatment 1 / 2 recruiting NCT05447702
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) treatment 2 recruiting NCT06078384
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC treatment 2 not_yet_recruiting NCT04925284
Study of XB002 in Subjects With Solid Tumors (JEWEL-101) treatment 1 active_not_recruiting NCT06533384
PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC treatment 3 recruiting NCT06337084
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors No drug interventions diagnostic 1 recruiting NCT06136884
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors No drug interventions treatment 1 recruiting NCT04134884
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer treatment 1 completed NCT04683679
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer treatment 2 recruiting NCT01372579
Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients treatment 2 unknown_status NCT06238479
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors No drug interventions treatment 1 recruiting NCT02161679
Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer treatment 2 withdrawn NCT03777579
A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC treatment 3 suspended NCT03620643
Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours other 2 active_not_recruiting NCT03165487
Comparison of the Breast Tumor Microenvironment No drug interventions Not Available Not Available recruiting NCT03281954
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo treatment 3 active_not_recruiting NCT05633654
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63) treatment 3 recruiting NCT04142554
Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer basic_science 1 withdrawn NCT04418154
Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients treatment 2 active_not_recruiting NCT03096054
A CR-UK Phase I Trial of LY3143921 No drug interventions treatment 1 active_not_recruiting NCT05274451
A Study to Investigate LYL797 in Adults with Solid Tumors No drug interventions treatment 1 recruiting NCT06435351
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy No drug interventions treatment 0 recruiting NCT04638751
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients No drug interventions Not Available Not Available recruiting NCT03193853
TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer treatment 2 completed NCT03599453
Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer treatment 0 completed NCT01676753
Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer treatment 1 completed NCT04332653
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors treatment 1 / 2 active_not_recruiting NCT01770353
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment other 1 completed NCT03891953
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. treatment 1 active_not_recruiting NCT03652077
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies treatment 1 completed NCT04861077
Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) No drug interventions diagnostic 0 not_yet_recruiting NCT02032277
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer treatment 3 completed NCT02401347
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors treatment 2 completed NCT02511847
Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib treatment 2 unknown_status NCT05078047
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO No drug interventions treatment 3 recruiting NCT05001347
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors treatment 2 completed NCT02983045
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors treatment 1 / 2 completed NCT03756298
Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer treatment 2 active_not_recruiting NCT04213898
SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer treatment 1 / 2 unknown_status NCT05192798
Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC treatment 2 recruiting NCT04248998
Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer treatment 2 active_not_recruiting NCT06492005
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer No drug interventions treatment 2 not_yet_recruiting NCT06225505
Early Detection of Triple Negative Breast Cancer Relapse No drug interventions diagnostic Not Available not_yet_recruiting NCT06440005
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors No drug interventions treatment 1 recruiting NCT03981705
Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer No drug interventions Not Available Not Available active_not_recruiting NCT06471205
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer No drug interventions treatment 2 recruiting NCT05955105
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies treatment 1 / 2 recruiting NCT06353997
Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients treatment 2 not_yet_recruiting NCT03586297
Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer No drug interventions Not Available Not Available recruiting NCT04676997
Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC) treatment 2 unknown_status NCT06451497
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors No drug interventions other 1 recruiting NCT05498597
AMT-151 in Patients With Selected Advanced Solid Tumours No drug interventions treatment 1 recruiting NCT02984683
Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer No drug interventions treatment 2 terminated NCT05491083
Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer treatment 1 / 2 recruiting NCT01292083
Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery treatment Not Available withdrawn NCT04468061
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC treatment 2 recruiting NCT05692661
A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer No drug interventions treatment 1 recruiting NCT05989828
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer treatment 1 not_yet_recruiting NCT03538028
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies treatment 1 completed NCT04148911
A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer treatment 3 active_not_recruiting NCT04427293
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) treatment 1 recruiting NCT03164993
Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer treatment 2 completed NCT03045393
Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC treatment 1 withdrawn NCT04180371
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression treatment 1 / 2 recruiting NCT04771871
MicroRNA Profiles in Triple Negative Breast Cancer treatment 2 unknown_status NCT05760378
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. treatment 3 recruiting NCT04722978
Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer treatment 3 recruiting NCT05302778
Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer No drug interventions Not Available Not Available recruiting NCT03920488
Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer No drug interventions Not Available Not Available recruiting NCT06367088
Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer treatment 2 recruiting NCT04254107
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer treatment 1 terminated NCT04030507
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer No drug interventions screening Not Available recruiting NCT05145907
Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors treatment 2 active_not_recruiting NCT00986609
MUC1 Vaccine for Triple-negative Breast Cancer other 0 completed NCT04230109
Sacituzumab Govitecan In TNBC treatment 2 recruiting NCT04580485
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors treatment 1 completed NCT03345485
Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors treatment 1 / 2 completed NCT05806385
Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers No drug interventions treatment 1 / 2 not_yet_recruiting NCT04958785
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer treatment 2 active_not_recruiting NCT04609215
ImmunoBreast - A Phase Ib Study No drug interventions treatment 1 / 2 unknown_status NCT05550415
The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer treatment 2 recruiting NCT03562637
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC treatment 3 recruiting NCT05266937
Atezolizumab Plus CArboplatin Plus Nab-paclitaxel treatment 2 active_not_recruiting NCT06355037
Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer treatment 2 recruiting NCT03186937
A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer No drug interventions basic_science 2 terminated NCT01969032
Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer treatment 2 completed NCT05174832
Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients treatment 2 recruiting NCT05329532
Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer treatment 1 / 2 recruiting NCT06351332
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC treatment 1 / 2 suspended NCT04244552
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies treatment 1 terminated NCT05435352
Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment No drug interventions Not Available Not Available recruiting NCT01631552
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer treatment 1 / 2 completed NCT06052852
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies treatment 1 / 2 recruiting NCT04457700
CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC No drug interventions Not Available Not Available unknown_status NCT05556200
A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs treatment 2 recruiting NCT04461600
A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer treatment 2 terminated NCT04742959
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors treatment 1 / 2 completed NCT05877859
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab No drug interventions Not Available Not Available recruiting NCT02950259
Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC) treatment 1 active_not_recruiting NCT01104259
Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer treatment 1 completed NCT04691375
A Study of PY314 in Subjects With Advanced Solid Tumors treatment 1 terminated NCT04296175
Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE) treatment 3 recruiting NCT01111175
Triple Negative Breast Cancer Biomarker Study No drug interventions Not Available Not Available completed NCT04745975
Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer treatment 2 unknown_status NCT06382142
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer treatment 3 recruiting NCT05954442
Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype treatment 3 recruiting NCT04060342
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma treatment 1 terminated NCT04107142
Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour No drug interventions other 1 unknown_status NCT03499899
A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer treatment 2 completed NCT05382299
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer treatment 3 recruiting NCT04441099
NBE-002 in Patients With Advanced Solid Tumors No drug interventions treatment 1 / 2 terminated NCT01276899
Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients No drug interventions Not Available Not Available completed NCT06182306
Prospective Evaluation of AI R&D Tool for Patient Stratification - MoA Evaluation in Triple Negative Breast Cancer (PEAR-MET) No drug interventions Not Available Not Available recruiting NCT05438706
A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer treatment 2 unknown_status NCT04335006
A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer. treatment 3 terminated NCT05234606
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors treatment 1 / 2 withdrawn NCT00998036
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors treatment 1 completed NCT03343613
A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors No drug interventions treatment 1 terminated NCT05057013
HMBD-001 in Advanced HER3 Positive Solid Tumours No drug interventions treatment 1 / 2 recruiting NCT05750719
BRCA and NACT in TNBC Patients No drug interventions Not Available Not Available completed NCT03733119
ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer treatment 2 terminated NCT04138719
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer treatment 2 unknown_status NCT03167619
Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) treatment 2 completed NCT03617341
Brain Monitoring for High Risk of Brain Metastases in Metastatic Breast Cancer No drug interventions Not Available Not Available unknown_status NCT04360941
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer other 1 recruiting NCT04602117
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer treatment 1 withdrawn NCT02012634
Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer No drug interventions Not Available Not Available unknown_status NCT03498716
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer treatment 3 terminated NCT03267316
A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors treatment 1 / 2 completed NCT04025216
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers treatment 1 terminated NCT04504916
A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) treatment 2 terminated NCT03244358
Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer treatment 2 terminated NCT05300958
Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer treatment 2 recruiting NCT02750358
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer treatment 2 active_not_recruiting NCT04577963
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors treatment 1 / 2 active_not_recruiting NCT06299163
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors No drug interventions treatment 1 recruiting NCT05821686
Efficacy of Interleukin-2 in Triple Negative Breast Cancer treatment 1 / 2 not_yet_recruiting NCT05783622
Study of JANX008 in Subjects with Advanced or Metastatic Solid Tumor Malignancies No drug interventions treatment 1 recruiting NCT05670925
A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC. No drug interventions treatment 2 recruiting NCT05037825
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors No drug interventions Not Available Not Available recruiting NCT01881230
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) treatment 2 / 3 completed NCT02632448
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer basic_science 1 / 2 recruiting NCT04443348
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) treatment 2 recruiting NCT01639248
Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC treatment 2 completed NCT06399757
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT02685657
Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer treatment 2 unknown_status NCT02615457
Huaier Granule in Treating Women With Triple Negative Breast Cancer No drug interventions treatment 4 recruiting NCT04432857
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors treatment 1 active_not_recruiting NCT03797326
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) treatment 2 active_not_recruiting NCT05868226
PRE-I-SPY Phase I/Ib Oncology Platform Program treatment 1 recruiting NCT05255666
Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM) treatment 2 withdrawn NCT05579366
PRO1184 for Advanced Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT03539965
Triple-negative Breast Cancer: a New Perspective on Biomarkers No drug interventions Not Available Not Available completed NCT02576665
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) treatment 1 terminated NCT04613674
A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) treatment 3 completed NCT06371274
A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC. treatment Not Available not_yet_recruiting NCT04464174
Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer treatment 2 completed NCT05076682
Reverse Triple Negative Immune Resistant Breast Cancer treatment 2 unknown_status NCT03621982
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors treatment 1 terminated NCT04105582
Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells No drug interventions basic_science 1 completed NCT03243331
An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer treatment 1 completed NCT04725331
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors treatment 1 / 2 recruiting NCT03992131
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) treatment 1 / 2 terminated NCT06358573
Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK No drug interventions treatment 2 not_yet_recruiting NCT06224673
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer treatment 2 not_yet_recruiting NCT03017573
Prospective Biobanking Study in Ovarian, Breast, Head and Neck and Cervical Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE) No drug interventions basic_science Not Available recruiting NCT05288127
Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature treatment 2 recruiting NCT01805076
MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer No drug interventions diagnostic 3 active_not_recruiting NCT04437160
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy treatment 2 recruiting NCT03170960
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors treatment 1 / 2 active_not_recruiting NCT05627960
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies No drug interventions treatment 1 recruiting NCT03362060
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer treatment 1 active_not_recruiting NCT05020860
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer treatment 2 recruiting NCT05076760
MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer treatment 1 recruiting NCT02993094
Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer treatment 1 / 2 terminated NCT05134194
A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer treatment 3 terminated NCT03473691
Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer treatment 0 withdrawn NCT02425891
A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) treatment 3 completed NCT02368691
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) treatment 2 terminated NCT03872791
A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer treatment 1 / 2 completed NCT05769491
Looking At Triple Negative Breast Cancer Patient Experience Patterns in Medical Trials No drug interventions Not Available Not Available not_yet_recruiting NCT03289962
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors treatment 1 active_not_recruiting NCT04118062
Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR) No drug interventions other Not Available active_not_recruiting NCT05181462
Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. treatment 1 / 2 recruiting NCT02365662
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor No drug interventions treatment 1 terminated NCT02681562
Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients treatment 2 unknown_status NCT04502680
Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients treatment 2 unknown_status NCT05645380
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC treatment 2 recruiting NCT04032080
LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer treatment 2 completed NCT06022029
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. treatment 1 recruiting NCT04510129
A Multicenter Cancer Biospecimen Collection Study No drug interventions Not Available Not Available recruiting NCT04095689
Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer treatment 2 suspended NCT06084689
Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures treatment 2 not_yet_recruiting NCT06171789
PRO1107 in Patients With Advanced Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT02657889
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer treatment 1 / 2 completed NCT03644589
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer treatment 2 withdrawn NCT01520389
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment treatment 1 completed NCT05846789
Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers treatment 2 recruiting NCT04947189
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer treatment 1 / 2 recruiting NCT05086692
A Beta-only IL-2 ImmunoTherapY Study treatment 1 / 2 recruiting NCT05843292
Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer treatment 4 not_yet_recruiting NCT06229392
A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer treatment 1 recruiting NCT02003092
RX-5902 Treatment of Subjects With Triple Negative Breast Cancer treatment 1 / 2 terminated NCT04445844
INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study treatment 2 recruiting NCT06081244
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) treatment 2 not_yet_recruiting NCT04282044
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies treatment 1 recruiting NCT02807844
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies treatment 1 / 2 completed NCT04907344
Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) treatment 2 / 3 not_yet_recruiting NCT03671044
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients treatment 3 recruiting NCT04434040
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) treatment 2 active_not_recruiting NCT06441240
Evaluation of Recurrence Risk Factors in Locally Advanced Breast Cancer Patients Underwent Neoadjuvant Chemotherapy. No drug interventions Not Available Not Available recruiting NCT02307240
Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors treatment 1 completed NCT04464967
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers treatment 1 / 2 withdrawn NCT01745367
Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer treatment 2 terminated NCT06229067
Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer treatment 2 not_yet_recruiting NCT04331067
Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer treatment 1 / 2 active_not_recruiting NCT04297267
A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant Chemotherapy treatment 2 unknown_status NCT03829501
Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer treatment 1 / 2 active_not_recruiting NCT04123704
Sitravatinib in Metastatic Breast Cancer treatment 2 terminated NCT03076372
A Study Evaluating MM-310 in Patients With Solid Tumors No drug interventions treatment 1 unknown_status NCT03292172
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer treatment 1 terminated NCT04770272
Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy treatment 2 active_not_recruiting NCT04664972
Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC treatment 2 completed NCT05953168
T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients treatment 2 not_yet_recruiting NCT04368468
Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BC No drug interventions Not Available Not Available completed NCT06246968
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer treatment 1 recruiting NCT01276769
Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer treatment 2 unknown_status NCT03094169
AVID100 in Advanced Epithelial Carcinomas No drug interventions treatment 1 / 2 terminated NCT06448169
Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer Not Available Not Available not_yet_recruiting NCT06465069
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors No drug interventions treatment 1 recruiting NCT04584112
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer treatment 1 completed NCT06532812
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer treatment 1 / 2 recruiting NCT05082610
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab treatment 1 recruiting NCT05730010
Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis No drug interventions Not Available Not Available completed NCT06407310
Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer treatment 2 not_yet_recruiting NCT04438681
Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients No drug interventions Not Available Not Available recruiting NCT03917381
GEN1046 Safety Trial in Patients With Malignant Solid Tumors treatment 1 / 2 active_not_recruiting NCT00031681
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) treatment 1 completed NCT06084481
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No drug interventions treatment 1 recruiting NCT05722795
Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC) other Not Available not_yet_recruiting NCT05916755
Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform Not Available Not Available recruiting NCT01677455
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer treatment 2 completed NCT04582955
Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy treatment Not Available unknown_status NCT03634150
Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer treatment 1 / 2 withdrawn NCT04291950
Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women No drug interventions Not Available Not Available withdrawn NCT05520723
Preventive stRategy for IMMU132-relatED AEs in TNBC - PRIMED treatment 2 active_not_recruiting NCT03752723
Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899) treatment 1 / 2 completed NCT04501523
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC treatment 2 recruiting NCT03243838
Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer treatment 2 completed NCT02981303
Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer treatment 2 completed NCT04192903
Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer treatment 2 unknown_status NCT06175390
Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer No drug interventions treatment 2 recruiting NCT05461690
Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency treatment 2 not_yet_recruiting NCT05296564
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers treatment 1 / 2 recruiting NCT04849364
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer treatment 2 recruiting NCT06150664
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies No drug interventions treatment 1 recruiting NCT06264921
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors No drug interventions treatment 1 recruiting NCT05336721
A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC treatment 2 recruiting NCT04877821
The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC treatment 2 recruiting NCT05955521
Exosome as the Prognostic and Predictive Biomarker in EBC Patients No drug interventions screening Not Available active_not_recruiting NCT02936102
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. treatment 1 active_not_recruiting NCT04067102
Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC treatment Not Available withdrawn NCT06225284
Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients treatment 2 not_yet_recruiting NCT04803084
Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment No drug interventions Not Available Not Available suspended NCT03457779
Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer No drug interventions diagnostic Not Available completed NCT04809779
PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC treatment 2 unknown_status NCT03799679
Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer No drug interventions treatment 4 unknown_status NCT06224387
CTS2190 Phase I /II Clinical Study in Patients No drug interventions treatment 1 / 2 recruiting NCT06577987
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies No drug interventions treatment 1 recruiting NCT05528133
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer No drug interventions treatment 2 recruiting NCT05403554
A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers No drug interventions treatment 1 recruiting NCT01091454
Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer treatment 2 completed NCT00951054
A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer treatment 2 completed NCT03983954
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors treatment 1 active_not_recruiting NCT06396754
Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatment in TNBC No drug interventions Not Available Not Available not_yet_recruiting NCT03454451
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers treatment 1 completed NCT03475953
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors treatment 1 / 2 recruiting NCT05714553
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours treatment 1 / 2 recruiting NCT05253053
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors treatment 1 / 2 recruiting NCT05169853
Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer No drug interventions Not Available Not Available active_not_recruiting NCT04099277
A Study of LY3435151 in Participants With Solid Tumors treatment 1 terminated NCT02580747
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso No drug interventions treatment 1 unknown_status NCT02641847
TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature treatment 2 / 3 active_not_recruiting NCT04145947
Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients No drug interventions Not Available Not Available recruiting NCT03654547
Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer treatment 1 active_not_recruiting NCT02543645
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer treatment 1 terminated NCT05144698
RAPA-201 Therapy of Solid Tumors treatment 1 / 2 recruiting NCT06460298
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer treatment 1 / 2 recruiting NCT03348098
Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer treatment 2 unknown_status NCT03872505
Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer treatment 2 withdrawn NCT03881605
MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients With Triple Negative or HER2+ MBC No drug interventions screening Not Available unknown_status NCT04405505
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC) treatment 3 unknown_status NCT04790305
Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer No drug interventions treatment 4 recruiting NCT05746897
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors treatment 1 recruiting NCT05891197
A Biomarker Screening Protocol for Participants With Solid Tumors No drug interventions Not Available Not Available recruiting NCT06318897
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer treatment 2 recruiting NCT03145961
A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients treatment 2 unknown_status NCT03775928
Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer treatment 2 unknown_status NCT01216111
Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN) treatment 3 completed NCT04268693
Bisphenol and Phthalate Exposures in Triple Negative Breast Cancer No drug interventions Not Available Not Available withdrawn NCT03812393
Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast treatment 2 active_not_recruiting NCT04913571
Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study treatment 2 unknown_status NCT03609671
Emotions Immunology and Breast Cancer No drug interventions supportive_care Not Available completed NCT05475678
Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer treatment 2 recruiting NCT05099978
Asian Multicenter Prospective Study of ctDNA Sequencing No drug interventions Not Available Not Available active_not_recruiting NCT03251378
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer treatment 1 active_not_recruiting NCT03915678
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors treatment 2 recruiting NCT03504488
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) treatment 1 / 2 recruiting NCT05902988
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer No drug interventions treatment 1 / 2 recruiting NCT05749588
FUSCC Refractory TNBC Platform Study (FUTURE2.0) treatment 2 recruiting NCT00707707
Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer treatment 1 completed NCT06371807
Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab treatment 2 not_yet_recruiting NCT05504707
DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer No drug interventions treatment 1 recruiting NCT04837209
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer treatment 2 recruiting NCT00813956
A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer treatment 2 completed NCT03401385
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) treatment 1 recruiting NCT03387085
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. treatment 1 / 2 terminated NCT03333915
Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors treatment 1 / 2 completed NCT03808337
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease No drug interventions treatment 2 recruiting NCT02247037
Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer No drug interventions Not Available Not Available completed NCT01234532
Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery treatment 2 terminated NCT01451632
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers treatment 1 completed NCT05909332
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03) No drug interventions treatment 3 recruiting NCT02639832
A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation. No drug interventions Not Available Not Available unknown_status NCT01306032
Phase II ABT-888 With Cyclophosphamide treatment 2 completed NCT04726332
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) treatment 1 terminated NCT02078752
A Study Of PF-06647263 In Patients With Advanced Solid Tumors No drug interventions treatment 1 terminated NCT06273852
A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors No drug interventions basic_science 0 recruiting NCT05809752
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) No drug interventions treatment 1 recruiting NCT03907800
Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer treatment 2 recruiting NCT04024800
Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer treatment 2 unknown_status NCT03057600
Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) treatment 2 completed NCT06309459
Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma No drug interventions Not Available Not Available completed NCT05082259
ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab health_services_research 1 recruiting NCT06134375
A Study of Tetrathiomolybdate (TM) Plus Capecitabine treatment 1 / 2 not_yet_recruiting NCT06519370
FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer treatment 3 not_yet_recruiting NCT02225470
Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes treatment 3 completed NCT04452370
Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer treatment 2 unknown_status NCT04296942
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) treatment 1 terminated NCT02583542
A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers treatment 1 / 2 unknown_status NCT04159142
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer treatment 2 unknown_status NCT04787042
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 treatment 1 / 2 active_not_recruiting NCT03674242
Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2) treatment 2 / 3 terminated NCT02938442
Vaccination of Triple Negative Breast Cancer Patients treatment 1 / 2 completed NCT03805399
FUSCC Refractory TNBC Umbrella (FUTURE) treatment 1 / 2 unknown_status NCT02685306
A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer treatment 2 withdrawn NCT01918306
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer treatment 1 / 2 terminated NCT05451849
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer treatment 1 / 2 active_not_recruiting NCT01151449
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer treatment 2 terminated NCT03154749
DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer treatment 2 completed NCT05112536
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer treatment 2 completed NCT01618136
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors treatment 1 / 2 completed NCT03829436
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers treatment 1 completed NCT03251313
PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients treatment 1 unknown_status NCT06202313
Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer treatment 2 not_yet_recruiting NCT05340413
Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. diagnostic 2 recruiting NCT04234113
Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors treatment 1 active_not_recruiting NCT04408118
First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC treatment 2 completed NCT05068141
A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC) treatment 2 unknown_status NCT02404441
Phase I/II Study of PDR001 in Patients With Advanced Malignancies treatment 1 / 2 completed NCT03358017
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer treatment 2 completed NCT05103917
A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC treatment 1 / 2 unknown_status NCT05565417
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas treatment 1 / 2 recruiting NCT02527434
Study of Tremelimumab in Patients With Advanced Solid Tumors treatment 2 completed NCT05347134
SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer treatment 3 active_not_recruiting NCT05128734
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) treatment 2 not_yet_recruiting NCT05620134
Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer treatment 1 / 2 recruiting NCT06355024
Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer treatment 2 not_yet_recruiting NCT02978716
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) treatment 2 terminated NCT03667716
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. treatment 1 completed NCT04677816
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients No drug interventions treatment 2 recruiting NCT04348916
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors treatment 1 terminated NCT03729596
MGC018 With or Without MGA012 in Advanced Solid Tumors treatment 1 / 2 terminated NCT04129996
A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS) treatment 2 unknown_status NCT06538896
Phase II Study of Tislelizumab Combined With Nab-Paclitaxel as First Line Treatment for Patients of Triple-negative Breast Cancer(TNBC) With Bone Metastasis treatment 2 not_yet_recruiting NCT05377996
A Study of XMT-1660 in Participants With Solid Tumors No drug interventions treatment 1 recruiting NCT05233696
Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC treatment 2 withdrawn NCT05498896
Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC treatment 2 active_not_recruiting NCT02315196
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer treatment 2 active_not_recruiting NCT03184558
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC treatment 2 terminated NCT02985658
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer Not Available Not Available no_longer_available NCT04225858
Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy No drug interventions treatment Not Available not_yet_recruiting NCT02375958
PCA062 in pCAD-positive Tumors. No drug interventions treatment 1 completed NCT04494958
Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer treatment 1 / 2 completed NCT03197935
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer treatment 3 completed NCT04481763
A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast treatment 1 / 2 recruiting NCT01931163
NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer treatment 2 completed NCT01818063
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer treatment 2 completed NCT04083963
Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer treatment 2 active_not_recruiting NCT03876886
The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency treatment 3 recruiting NCT05774886
Implantable Microdevice for TNBC - Pilot Study No drug interventions treatment 1 withdrawn NCT05382286
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer treatment 3 recruiting NCT06246786
Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer) treatment 0 recruiting NCT03616886
Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC treatment 1 / 2 active_not_recruiting NCT05848739
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors treatment 1 recruiting NCT05358639
Combination of Olaparib and Navitoclax in Women With HGSC and TNBC treatment 1 recruiting NCT04301739
to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) treatment 3 not_yet_recruiting NCT06497322
Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment No drug interventions treatment Not Available not_yet_recruiting NCT06449222
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy No drug interventions treatment 2 recruiting NCT05453825
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors treatment 2 recruiting NCT03444025
Neoadjuvant Goserelin for Triple Negative Breast Cancer treatment 2 unknown_status NCT04320030
[18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers diagnostic 2 completed NCT02616848
Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers treatment 1 unknown_status NCT05632848
Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients treatment 2 recruiting NCT03639948
Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer treatment 2 active_not_recruiting NCT01982448
Cisplatin vs Paclitaxel for Triple Negative Breast Cancer treatment 2 completed NCT02580448
CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) treatment 1 / 2 completed NCT01695057
Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer treatment Not Available withdrawn NCT01986426
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab treatment 1 completed NCT03932526
Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer treatment 2 unknown_status NCT04442126
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors No drug interventions treatment 1 / 2 terminated NCT04768426
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer treatment 2 recruiting NCT06418126
Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast Cancer No drug interventions other Not Available recruiting NCT01525966
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer treatment 2 active_not_recruiting NCT05485766
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer treatment 2 recruiting NCT03175666
QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy treatment 1 / 2 withdrawn NCT05113966
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer treatment 2 completed NCT03487666
OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease treatment 2 active_not_recruiting NCT06328465
fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases No drug interventions diagnostic Not Available recruiting NCT03090165
Ribociclib and Bicalutamide in AR+ TNBC treatment 1 / 2 recruiting NCT04595565
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer treatment 3 active_not_recruiting NCT06393374
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) treatment 3 recruiting NCT05115474
Study of Screening Brain MRIs in Stage IV Breast Cancer No drug interventions Not Available Not Available recruiting NCT06087120
Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer. No drug interventions Not Available Not Available recruiting NCT02348320
Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy No drug interventions treatment 1 completed NCT03567720
Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC treatment 2 active_not_recruiting NCT02413320
Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer treatment 2 completed NCT04750382
A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer treatment 1 / 2 unknown_status NCT05492682
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer treatment 1 recruiting NCT03720431
TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer treatment 1 unknown_status NCT03576131
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors No drug interventions treatment 1 / 2 terminated NCT02637531
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 treatment 1 unknown_status NCT04142931
Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors treatment 1 unknown_status NCT05460273
A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) treatment 1 / 2 active_not_recruiting NCT03982173
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors treatment 2 withdrawn NCT03674827
Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC No drug interventions treatment 1 terminated NCT03394027
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma treatment 2 completed NCT04802876
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors treatment 2 recruiting NCT04085276
Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment treatment 3 active_not_recruiting NCT05390476
Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial treatment 2 recruiting NCT04178460
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment treatment 1 terminated NCT05806060
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer treatment 3 recruiting NCT03356860
Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. treatment 1 / 2 completed NCT02393794
Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) treatment 1 / 2 active_not_recruiting NCT01307891
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer treatment 2 completed NCT02071862
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors treatment 1 completed NCT03075462
A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients treatment 1 completed NCT03318562
A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC treatment 2 terminated NCT05680662
The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism treatment 0 not_yet_recruiting NCT06259162
LAG3 Expression in Triple Negative Breast Cancer No drug interventions screening Not Available recruiting NCT03808662
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung No drug interventions treatment 2 active_not_recruiting NCT04362462
Molecular Profiling After Neoadjuvant Chemotherapy for Triple-negative Breast Cancer No drug interventions Not Available Not Available unknown_status NCT04758780
Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients No drug interventions diagnostic 2 recruiting NCT03168880
A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer treatment 3 active_not_recruiting NCT04403529
Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer No drug interventions treatment 3 unknown_status NCT06245889
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC treatment 2 recruiting NCT03197389
Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer. basic_science 0 completed NCT04807192
CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC) treatment 2 recruiting NCT05763992
Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial No drug interventions treatment 2 recruiting NCT06562192
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers treatment 1 not_yet_recruiting NCT03435640
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies treatment 1 / 2 terminated NCT03199040
Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy treatment 1 terminated NCT03750240
Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy No drug interventions diagnostic Not Available terminated NCT05111067
Molecular Subtyping of Triple-negative Breast Cancer and African Ancestry-related Immunogenicity No drug interventions Not Available Not Available completed NCT02768701
Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer treatment 2 completed NCT05552001
Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer treatment 3 recruiting NCT03945604
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC treatment 1 completed NCT03358004
the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment treatment 2 terminated NCT03997968
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors treatment 1 / 2 active_not_recruiting NCT02977468
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer treatment 1 recruiting NCT06347068
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells treatment 1 recruiting NCT02644369
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors treatment 2 active_not_recruiting NCT03849469
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors treatment 1 completed NCT03901469
A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer treatment 2 terminated NCT06349512
68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT) No drug interventions diagnostic Not Available not_yet_recruiting NCT05872412
Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer treatment 2 not_yet_recruiting NCT06281210
Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery No drug interventions treatment Not Available recruiting NCT05910710
Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer No drug interventions Not Available Not Available recruiting NCT02427581
Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy treatment 1 withdrawn NCT05809895
Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer treatment 2 withdrawn NCT03761914
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers treatment 1 / 2 active_not_recruiting NCT06220214
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer diagnostic 0 recruiting NCT02259114
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) treatment 1 completed NCT05546255
Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer treatment 2 unknown_status NCT05309655
Cardiac Outcomes With Near-Complete Estrogen Deprivation treatment 0 recruiting NCT04690855
A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer treatment 2 terminated NCT03301350
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer treatment 2 completed NCT03775850
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors treatment 1 completed NCT02802423
Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. treatment 1 / 2 not_yet_recruiting NCT04068623
Correlation Between TILs and Blood Cell Counts in Triple Negative Breast Cancer Patients No drug interventions Not Available Not Available recruiting NCT04177108
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer treatment 3 completed NCT00733408
Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer treatment 2 completed NCT03449108
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas treatment 2 active_not_recruiting NCT02595138
Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer treatment 3 unknown_status NCT01391143
Safety Study of MGA271 in Refractory Cancer treatment 1 completed NCT05862064
PD-1 Combined With Adjuvant Chemotherapy and Antivascular Therapy Versus Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer treatment 3 recruiting NCT01042379
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer treatment 2 recruiting NCT05914961
Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer No drug interventions Not Available Not Available recruiting NCT06387628
LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer treatment 2 recruiting NCT03123211
Expanded Access to Veliparib Not Available Not Available no_longer_available NCT05219578
RTX-224 Monotherapy in Patients With Solid Tumors No drug interventions treatment 1 / 2 terminated NCT06189209
Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) treatment 2 recruiting NCT06230185
ctDNA Based MRD Testing for NAC Monitoring in TNBC No drug interventions Not Available Not Available recruiting NCT05768932
BAL0891 in Patients With Advanced Solid Tumors treatment 1 recruiting NCT03549000
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. No drug interventions treatment 1 terminated NCT05582499
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy treatment 2 recruiting NCT05555706
Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer treatment 2 / 3 recruiting NCT04799249
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) treatment 3 completed NCT06404736
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer treatment 2 not_yet_recruiting NCT03875313
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors treatment 1 / 2 terminated NCT05957939
Targeting Metastatic Breast Cancers by Alkaline Glucosodiene Molecules Via a Metabolic Pathway Phase I Clinical Trial No drug interventions treatment 1 not_yet_recruiting NCT02178722
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers treatment 1 / 2 completed NCT05402722
Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer treatment 2 unknown_status NCT03719326
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies treatment 1 completed NCT05107674
A Study of NX-1607 in Adults With Advanced Malignancies treatment 1 recruiting NCT02698176
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) treatment 1 terminated NCT05928780
An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2) treatment 1 / 2 not_yet_recruiting NCT05209529
Chemo-free BRCA-targeted Neoadjuvant Strategy treatment 2 withdrawn NCT06568692
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer treatment 2 recruiting NCT05490472
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT04755868
Talazoparib Maintenance Therapy in Triple-negative Breast Cancer treatment 2 unknown_status NCT06059469
PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer. No drug interventions diagnostic 2 recruiting NCT05390710
PhI to Solid Tumors and PhII to Locally Advanced or mTNBC treatment 1 completed NCT05698238
Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours No drug interventions treatment 1 not_yet_recruiting NCT05949021
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer treatment 2 recruiting NCT05660083
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) treatment 2 recruiting NCT05891171
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers treatment 1 recruiting NCT03554109
QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine treatment 2 withdrawn NCT01884285
AZD8186 First Time In Patient Ascending Dose Study treatment 1 completed NCT06431100
a Single-arm, Single-center, Open Clinical Study No drug interventions Not Available Not Available recruiting NCT04674306
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer No drug interventions treatment 0 recruiting NCT03742349
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). treatment 1 terminated NCT05999149
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) treatment 3 recruiting NCT02819518
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) treatment 3 completed NCT06476119
OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes No drug interventions Not Available Not Available not_yet_recruiting NCT04424641
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors No drug interventions treatment 1 / 2 terminated NCT05585034
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors treatment 1 recruiting NCT05383196
Onvansertib + Paclitaxel In TNBC treatment 1 / 2 recruiting NCT03855358
A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC) treatment 1 unknown_status NCT02316457
RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID No drug interventions treatment 1 completed NCT05088057
Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer treatment 2 recruiting NCT05491226
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation treatment 2 recruiting NCT05062174
Breast Cancer BRCA1 Carriers: a Pilot Study Not Available Not Available withdrawn NCT05834582
Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer treatment 2 recruiting NCT03746431
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection No drug interventions treatment 1 / 2 recruiting NCT03911973
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers treatment 1 / 2 active_not_recruiting NCT05491694
To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer treatment 2 not_yet_recruiting NCT06534762
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study treatment 2 recruiting NCT04706962
TH1902 in Patients With Advanced Solid Tumors No drug interventions treatment 1 recruiting NCT06125080
The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study treatment 2 recruiting NCT04395989
An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. treatment 2 active_not_recruiting NCT03207867
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma treatment 2 terminated NCT05541367
Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer No drug interventions Not Available Not Available recruiting NCT03219268
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms treatment 1 completed NCT05396612
Role of the Immune Environment in Response to Therapy in Breast Cancer No drug interventions Not Available Not Available recruiting NCT03893955
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors treatment 1 active_not_recruiting NCT03361800
Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC basic_science 0 terminated NCT02531425
Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC No drug interventions treatment 1 completed NCT05918133
A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC treatment 1 / 2 recruiting NCT05581004
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors treatment 1 recruiting NCT06210438
SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases treatment 2 not_yet_recruiting NCT03752398
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) treatment 1 completed